Topic

All

21
Feb
2024

Joy, Gratitude and Next Steps for Timmerman Traverse

Reporting this morning from Tanzania. I’m feeling joyful and grateful. My latest biotech team wrapped up another $1 million Timmerman Traverse fundraising campaign for the Damon Runyon Cancer Research Foundation. All 20 members of the team reached the summit of Kilimanjaro, the highest peak in Africa at 19,341 feet. We raised awareness of Damon Runyon’s national network of brilliant, brave...
Read More
17
Feb
2024

New Medical Podcast (Like Winter and the 2024 Red Sox) Offers Bleak Outlook, While Four Books Instill Hope

As Bostonians tentatively emerge from the bleak cold of another New England winter and begin to search for signs of spring, we instinctively turn to the Red Sox.  Unfortunately, I am informed by my daughters that the team’s prospects appear dismal this season, so we’ll need to look elsewhere for hope. We might consider instead Boston’s other great preoccupation: biomedical...
Read More
9
Feb
2024

Botox: A Luminous Example of Field Discovery

In this weekend’s Wall Street Journal, I review Death To Beauty, a new book by Dr. Eugene Helveston. It’s about the fascinating history of botulinum toxin and the California ophthalmologist, Alan Scott, who drove it into clinical use. The book review, of course, speaks for itself, but I wanted to highlight for TR readers an aspect of the story that...
Read More
9
Jan
2024

Investing in Healthy Aging: Jens Eckstein on The Long Run

Jens Eckstein is today’s guest on The Long Run. He’s an investment partner at Hevolution Foundation. It’s a Saudi Arabia-backed fund that supports basic research in healthy aging and invests in startups with partners to translate that science into interventions that help people live healthier, longer lives. These efforts are sometimes branded as increasing “healthspan” if not necessarily “lifespan.” Jens...
Read More
27
Dec
2023

Give to the Next Generation of Scientists

This is the time of year when many people sit down and think about the causes they want to support. I’m asking you to consider donating today to young scientists through the Damon Runyon Cancer Research Foundation. Why Young Scientists? Our system for funding science doesn’t do enough to support young people. The average age of a first-time NIH grant...
Read More
26
Dec
2023

Bispecific Antibodies for Cancer: Shelley Force Aldred and Nathan Trinklein on The Long Run

Today, I have a dynamic duo of scientific entrepreneurs on the show – Shelley Force Aldred and Nathan Trinklein. They are the co-founders of San Francisco-based Rondo Therapeutics. The company raised $67 million in a Series A financing announced in March 2022. Shelley is the CEO and Nathan is the chief scientific officer. Rondo is developing bispecific T-cell engaging antibodies...
Read More
21
Dec
2023

The Cultures of Large and Small Pharmas, plus: Can They Overcome The “Productivity Paradox” and Seize the AI Moment?

Spurred by several questions I’ve received from students and trainees, today’s year-end column examines some of the ways large biopharma companies are fundamentally different from small biotech companies and startups.  We’ll also ask whether biopharma can overcome new technology’s dreaded “productivity paradox” and learn, quickly, how to apply AI to accelerate drug development. Large Pharmas vs Smaller Companies (Including Startups)...
Read More
1 2 3 70